Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2011 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
The following terms were ignored: %, %
The following terms were not found in PubMed: 20bat1
Page 1
An open-label multiyear study of sargramostim-treated Parkinson's disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers.
Transl Neurodegener. 2023 May 22;12(1):26. doi: 10.1186/s40035-023-00361-1.
Transl Neurodegener. 2023.
PMID: 37217980
Free PMC article.
BACKGROUND: The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer's disease. The safety, tolerability, and mechanisms of action in Pa …
BACKGROUND: The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune …
Overview of how N32 and N34 elovanoids sustain sight by protecting retinal pigment epithelial cells and photoreceptors.
Bazan NG.
Bazan NG.
J Lipid Res. 2021;62:100058. doi: 10.1194/jlr.TR120001137. Epub 2021 Mar 2.
J Lipid Res. 2021.
PMID: 33662383
Free PMC article.
Review.
Here, we review the structures and stereochemistry of novel elovanoid (ELV)-N32 and ELV-N34 to be ELV-N32: (14Z,17Z,20R,21E,23E,25Z,27S,29Z)-20,27-dihydroxydo-triaconta-14,17,21,23,25,29-hexaenoic acid; ELV-N34: (16Z,19Z,22R,23E,25E,27Z,29S,31Z)-22,29-dihydroxytetra-triaco …
Here, we review the structures and stereochemistry of novel elovanoid (ELV)-N32 and ELV-N34 to be ELV-N32: (14Z,17Z,20R,21E,23E,25Z,27S …
Item in Clipboard
Single-molecule atomic force microscopy force spectroscopy study of Aβ-40 interactions.
Kim BH, Palermo NY, Lovas S, Zaikova T, Keana JF, Lyubchenko YL.
Kim BH, et al.
Biochemistry. 2011 Jun 14;50(23):5154-62. doi: 10.1021/bi200147a. Epub 2011 May 17.
Biochemistry. 2011.
PMID: 21553928
Free PMC article.
Misfolding and aggregation of amyloid beta-40 (Abeta-40) peptide play key roles in the development of Alzheimer's disease (AD). However, very little is known about the molecular mechanisms underlying these molecular processes. ...
Misfolding and aggregation of amyloid beta-40 (Abeta-40) peptide play key roles in the development of Alzheimer's disease …
Item in Clipboard
Cite
Cite